A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-Child Bearing Potential
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2010
At a glance
- Drugs AZD 6280 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 Dec 2010 Actual end date changed from 1 Sep 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.
- 08 Dec 2010 Actual initiation date changed from 1 Apr 2008 to 1 Mar 2008 as reported by ClinicalTrials.gov.
- 20 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.